Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–10 of 10 results
Advanced filters: Author: "Emily Waltz" Clear advanced filters

  • Vaccines inhaled through the mouth or nose might stop the coronavirus in its tracks, although there’s little evidence from human trials so far.

    • Emily Waltz
    News
    Nature
    Volume: 609, P: 240-242

  • Authors of some of the most highly cited Nature Biotechnology nonbiomedical papers from the past 20 years discuss their work and challenges for their fields.

    • Laura DeFrancesco
    • Charles Schmidt
    • Emily Waltz
    Special Features
    Nature Biotechnology
    Volume: 34, P: 267-269

  • Authors of some of the most highly cited Nature Biotechnology papers that describe research tools discuss their work and challenges for their fields.

    • Anna Azvolinsky
    • Laura DeFrancesco
    • Sarah Webb
    Special Features
    Nature Biotechnology
    Volume: 34, P: 256-261

  • Authors of some of the most highly cited Nature Biotechnology biomedical papers from the past 20 years discuss their work and challenges for their fields.

    • Anna Azvolinsky
    • Charles Schmidt
    • Sarah Webb
    Special Features
    Nature Biotechnology
    Volume: 34, P: 262-266

  • Regulators, scientists and surgeons are preparing the groundwork for human trials of engineered pig organs—and industry is starting to take notice.

    • Emily Waltz
    Special Features
    Nature Biotechnology
    Volume: 35, P: 1133-1138

  • The US National Cancer Institute has completed its funding for nanobiotech projects, but the debate about its value to startups lingers.

    • Emily Waltz
    Comments & Opinion
    Bioentrepreneur
    P: 1-3

  • In recent years, a number of universities have created graduate degrees in biotech and business. Although it's still too early to measure their value, it appears that they are already inspiring debate and some startup activity.

    • Emily Waltz
    Comments & Opinion
    Bioentrepreneur
    P: 1-2

  • New York City is crowing about the long-awaited arrival of a new biotech park, but the city will have to overcome its image as a financial and fashion capital before it captures the interest of biotech startups.

    • Emily Waltz
    Comments & Opinion
    Bioentrepreneur
    P: 1-3